Cited by 505Statistical Methods in Clinical TrialsAdvanced Causal Inference TechniquesMeta-analysis and systematic reviews

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

Open access

Kent, David M, Rothwell, Peter M, Ioannidis, John PA, Altman, Doug G, Hayward, Rodney A·2010·Trials

DOI 10.1186/1745-6215-11-85PMC PMC2928211

Open this paper in CoChat — free account Open PDF

Abstract

Mounting evidence suggests that there is frequently considerable variation in the risk of the outcome of interest in clinical trial populations. These differences in risk will often cause clinically important heterogeneity in treatment effects (HTE) across the trial population, such that the balance between treatment risks and benefits may differ substantially between large identifiable patient subgroups; the "average" benefit observed in the summary result may even be non-representative of the treatment effect for a typical patient in the trial. Conventional subgroup analyses, which examine whether specific patient characteristics modify the effects of treatment, are usually unable to detect even large variations in treatment benefit (and harm) across risk groups because they do not account for the fact that patients have multiple characteristics simultaneously that affect the likelihood of treatment benefit. Based upon recent evidence on optimal statistical approaches to assessing HTE, we propose a framework that prioritizes the analysis and reporting of multivariate risk-based HTE and suggests that other subgroup analyses should be explicitly labeled either as primary subgroup analyses (well-motivated by prior evidence and intended to produce clinically actionable results) or secondary (exploratory) subgroup analyses (performed to inform future research). A standardized and transparent approach to HTE assessment and reporting could substantially improve clinical trial utility and interpretability.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1745-6215-11-85

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Self-citation
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 1×
“Additionally, because conventional subgroup analyses involve multiple comparisons and involve splitting the overall sample to smaller sub-samples, they are both under-powered for detecting genuine subgroup effects (prone to false-negatives), and even more commonly they are prone to false positive findings [25-31].”
BackgroundSelf-citation
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI
Antman, E. M., Cohen, M. C., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalán, R., Radley, D. R., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,221
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,168
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
Yusuf, S., Zucker, D. M., Passamani, E. R., Peduzzi, P. N., Takaro, T., Fisher, L. D., Kennedy, J. W., Davis, K. B., Killip, T., Norris, R. M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91963-1 · Cited by 2,125
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials
(1996) · The Lancet · doi:10.1016/s0140-6736(96)04292-4 · Cited by 1,564

Show all 72 references

Sorted by citations

What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis
Veerbeek, J. M., van Wegen, E., van Peppen, R., van der Wees, P. J., Hendriks, E., Rietberg, M., & Kwakkel, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087987 · Cited by 1,203
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
‡ (2012) · The Lancet · doi:10.1016/s0140-6736(12)60768-5 · Cited by 1,204
A catalogue of reporting guidelines for health research
Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02234.x · Cited by 1,047
Self-citation
A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Elmunzer, B. J., Scheiman, J. M., Lehman, G. A., Chak, A., Mosler, P., Higgins, P., Hayward, R. A., Romagnuolo, J., Elta, G. H., Sherman, S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111103 · Cited by 741
Self-citation
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668
Self-citation
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke
Kent, D. M., Ruthazer, R., Weimar, C., Mas, J., Serena, J. L., Homma, S., Angelantonio, E. D., Tullio, M. R. D., Lutz, J. S., Elkind, M. S. V., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a08d59 · Cited by 647
Self-citation
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Standard 6: Age Groups for Pediatric Trials
Williams, K. J., Thomson, D., Seto, I., Contopoulos‐Ioannidis, D. G., Ioannidis, J. P. A., Curtis, S. J., Constantin, E., Batmanabane, G., Hartling, L., & Klassen, T. P. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0055i · Cited by 555
Self-citation
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E. W., & Klaveren, D. V. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 518
Self-citation
The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement
Kent, D. M., Paulus, J. K., van Klaveren, D., D'Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P. A., Patrick-Lake, B., Morton, S., Pencina, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m18-3667 · Cited by 469
Self-citation
Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials
Zulman, D. M., Sussman, J. B., Chen, X., Cigolle, C. T., Blaum, C. S., & Hayward, R. A. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1629-x · Cited by 405
Self-citation
Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis
Negeri, Z., Levis, B., Sun, Y., He, C., Krishnan, A., Wu, Y., Bhandari, P. M., Neupane, D., Brehaut, E., Benedetti, A., et al. (2021) · BMJ · doi:10.1136/bmj.n2183 · Cited by 414
Quasi-experimental design
Maciejewski, M. L. (2018) · Biostatistics & Epidemiology · doi:10.1080/24709360.2018.1477468 · Cited by 406
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 328
Three simple rules to ensure reasonably credible subgroup analyses
Burke, J. F., Sussman, J. B., Kent, D. M., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h5651 · Cited by 312
Self-citation
Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock
Leligdowicz, A., Dodek, P., Norena, M., Wong, H., Kumar, A., & Kumar, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1875oc · Cited by 292
Single-patient (n-of-1) trials: A pragmatic clinical decision methodology for patient-centered comparative effectiveness research
Duan, N., Kravitz, R. L., & Schmid, C. H. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.04.006 · Cited by 239
Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.
Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806802 · Cited by 228
Self-citation
Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 228
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity
Yavchitz, A., Ravaud, P., Altman, D. G., Moher, D., Hrobjartsson, A., Lasserson, T., & Boutron, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.020 · Cited by 224
Self-citation
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection
Justice, A. C., Modur, S. P., Tate, J. P., Althoff, K. N., Jacobson, L. P., Gebo, K. A., Kitahata, M. M., Horberg, M. A., Brooks, J. T., Buchacz, K. A., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31827df36c · Cited by 222
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation
Takahashi, K., Serruys, P. W. J. C., Fuster, V., Farkouh, M. E., Spertus, J. A., Cohen, D. J., Park, S., Park, D., Ahn, J., Kappetein, A. P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32114-0 · Cited by 218
Self-citation
Differences between opioids: pharmacological, experimental, clinical and economical perspectives
Drewes, A. M., Jensen, R. D., Nielsen, L. M., Droney, J., Christrup, L. L., Arendt‐Nielsen, L., Riley, J. L., & Dahan, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04317.x · Cited by 207
Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder
Kessler, R. C., van Loo, H. M., Wardenaar, K. J., Bossarte, R. M., Brenner, L. A., Ebert, D. D., de Jonge, P., Nierenberg, A. A., Rosellini, A. J., Sampson, N. A., et al. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000020 · Cited by 193
Conceptual, Methodological, and Ethical Problems in Communicating Uncertainty in Clinical Evidence
Han, P. K. J. (2012) · Medical Care Research and Review · doi:10.1177/1077558712459361 · Cited by 195
Estimating treatment effects for individual patients based on the results of randomised clinical trials
Dorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ · doi:10.1136/bmj.d5888 · Cited by 177
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration
Kent, D. M., Klaveren, D. V., Paulus, J. K., D’Agostino, R. B., Goodman, S. N., Hayward, R. A., Ioannidis, J. P. A., Patrick‐Lake, B., Morton, S. C., Pencina, M. J., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3668 · Cited by 183
Self-citation
Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement
Arnold, S. V., Afilalo, J., Spertus, J. A., Tang, Y., Baron, S. J., Jones, P. G., Reardon, M. J., Yakubov, S. J., Adams, D. H., & Cohen, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.762 · Cited by 164
Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study
Robinson, J. L., Corrada, M. M., Kovács, G. G., Dominique, M. A., Caswell, C., Xie, S. X., Lee, V. M. ‐., Kawas, C. H., & Trojanowski, J. Q. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1872-5 · Cited by 166
A Framework for Crafting Clinical Practice Guidelines That Are Relevant to the Care and Management of People with Multimorbidity
Uhlig, K., Leff, B., Kent, D., Dy, S., Brunnhuber, K., Burgers, J. S., Greenfield, S., Guyatt, G., High, K., Leipzig, R., et al. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2659-y · Cited by 158
Self-citation
Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials
Kent, D. M., Nelson, J., Dahabreh, I. J., Rothwell, P. M., Altman, D. G., & Hayward, R. A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw118 · Cited by 161
Self-citation
A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research
Varadhan, R., Segal, J. B., Boyd, C. M., Wu, A. W., & Weiss, C. O. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.009 · Cited by 151
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program
Sussman, J. B., Kent, D. M., Nelson, J. P., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h454 · Cited by 143
Self-citation
Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence
Dahabreh, I. J., Hayward, R. A., & Kent, D. M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw125 · Cited by 140
Self-citation
Heterogeneity Is a Hallmark of Traumatic Brain Injury, Not a Limitation: A New Perspective on Study Design in Rehabilitation Research
Covington, N. V., & Duff, M. C. (2021) · American Journal of Speech-Language Pathology · doi:10.1044/2020_ajslp-20-00081 · Cited by 141
Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
Miller, M. E., Williamson, J. D., Gerstein, H. C., Byington, R. P., Cushman, W. C., Ginsberg, H. N., Ambrosius, W. T., Lovato, L., Applegate, W. B., & for the ACCORD Investigators (2013) · Diabetes Care · doi:10.2337/dc13-1545 · Cited by 128
Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials
Venema, E., Mulder, M. J. H. L., Roozenbeek, B., Broderick, J. P., Yeatts, S. D., Khatri, P., Berkhemer, O. A., Emmer, B. J., Roos, Y. B. W. E. M., Majoie, C. B. L. M., et al. (2017) · BMJ · doi:10.1136/bmj.j1710 · Cited by 130
Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial
Baum, A., Scarpa, J. R., Bruzelius, E., Tamler, R., Basu, S., & Faghmous, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30176-6 · Cited by 125
Indomethacin with or without Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis after ERCP: A Randomised Non-Inferiority Trial
Elmunzer, B. J., Foster, L. D., Serrano, J., Coté, G. A., Edmundowicz, S. A., Wani, S. B., Shah, R., Bang, J. Y., Varadarajulu, S., Singh, V. K., et al. (2026) · CRC Press eBooks · doi:10.1201/9781003597162-42 · Cited by 121
“Reports of My Death Were Greatly Exaggerated”: Behavior Genetics in the Postgenomic Era
Harden, K. P. (2020) · Annual Review of Psychology · doi:10.1146/annurev-psych-052220-103822 · Cited by 125
Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)
Yoo, A. J., Berkhemer, O. A., Fransen, P. S. S., van den Berg, L. A., Beumer, D., Lingsma, H. F., Schonewille, W. J., Sprengers, M. E. S., van den Berg, R., van Walderveen, M. A. A., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00124-1 · Cited by 118
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial
Schreuder, F. H. B. M., van Nieuwenhuizen, K. M., Hofmeijer, J., Vermeer, S. E., Kerkhoff, H., Zock, E., Luijckx, G. J., Messchendorp, G., van Tuijl, J. H., Bienfait, H. P., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00298-2 · Cited by 112
A Systematic Review on the Development of Asthma and Allergic Diseases in Relation to International Immigration: The Leading Role of the Environment Confirmed
Cabieses, B., V, Uphoff, E., Pinart, M., Antó, J. M., & Wright, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105347 · Cited by 111
The proposed ‘concordance-statistic for benefit’ provided a useful metric when modeling heterogeneous treatment effects
Klaveren, D. V., Steyerberg, E. W., Serruys, P. W. J. C., & Kent, D. M. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.10.021 · Cited by 111
Self-citation
COMPREHENSIVE REVIEW OF FACTORS IMPLICATED IN THE HETEROGENEITY OF RESPONSE IN DEPRESSION: Review: Heterogeneity in Depression
Carter, G. C., Cantrell, R. A., Zarotsky, V., Haynes, V. S., Phillips, G., Alatorre, C. I., Goetz, I., Paczkowski, R., & Marangell, L. B. (2012) · Depression and Anxiety · doi:10.1002/da.21918 · Cited by 109
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A. A., Armstrong, P. W., Prabhakaran, D., Hafley, G. E., Lokhnygina, Y. V., Boden, W. E., Hamm, C. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61451-8 · Cited by 111
The Risk of Paradoxical Embolism (RoPE) Study: Developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke
RoPE Study Investigators, Kent, D. M., & Thaler, D. E. (2011) · Trials · doi:10.1186/1745-6215-12-185 · Cited by 109
Self-citation
Clinical Prediction Models for Cardiovascular Disease
Wessler, B. S., Lana Lai, Y. H., Kramer, W., Cangelosi, M. J., Raman, G., Lutz, J. S., & Kent, D. M. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.001693 · Cited by 106
Self-citation
Risk-Targeted Lung Cancer Screening
Kumar, V., Cohen, J. T., Klaveren, D. V., Soeteman, D. I., Wong, J. B., Neumann, P. J., & Kent, D. M. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1401 · Cited by 106
Self-citation
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Goligher, E. C., Lawler, P. R., Jensen, T. P., Talisa, V. B., Berry, L. R., Lorenzi, E., McVerry, B. J., Chang, C. H., Leifer, E., Bradbury, C. A., et al. (2023) · JAMA · doi:10.1001/jama.2023.3651 · Cited by 103
Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee
Stevenson, W. G., Hernandez, A. F., Carson, P. E., Fang, J. C.-T., Katz, S. D., Spertus, J. A., Sweitzer, N. K., Tang, W. H. W., Albert, N. M., Butler, J., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.12.004 · Cited by 102
Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency
Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 108
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Meyer, N. J., Reilly, J. P., Anderson, B. J., Palakshappa, J. A., Jones, T. K., Dunn, T. G., Shashaty, M. G. S., Feng, R., Christie, J. D., & Opal, S. M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002749 · Cited by 102
Evidence-Based Medicine Versus Personalized Medicine
de León, J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182491383 · Cited by 98
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
Development of Clinical Practice Guidelines
Hollon, S. D., Areán, P. A., Craske, M. G., Crawford, K. A., Kivlahan, D. R., Magnavita, J. J., Ollendick, T. H., Sexton, T. L., Spring, B. J., Bufka, L. F., et al. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185529 · Cited by 103
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
Salman, R. A., Minks, D. P., Mitra, D., Rodrigues, M. A., Bhatnagar, P., du Plessis, J. C., Joshi, Y., Dennis, M. S., Murray, G. D., Newby, D. E., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30184-x · Cited by 94
Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much
Moynihan, R. N., Henry, D. A., & Moons, K. G. M. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001655 · Cited by 94
Effect of Mobile Device–Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain
Kravitz, R. L., Schmid, C. H., Marois, M., Wilsey, B. L., Ward, D., Hays, R. D., Duan, N., Wang, Y., MacDonald, S. T., Jerant, A. F., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3981 · Cited by 91
Selecting Optimal Subgroups for Treatment Using Many Covariates
VanderWeele, T. J., Luedtke, A. R., van der Laan, M. J., & Kessler, R. C. (2019) · Epidemiology · doi:10.1097/ede.0000000000000991 · Cited by 95
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses
Wallach, J. D., Sullivan, P. G., Trepanowski, J. F., Steyerberg, E. W., & Ioannidis, J. P. A. (2016) · BMJ · doi:10.1136/bmj.i5826 · Cited by 89
Self-citation
Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes
Tanniou, J., van der Tweel, I., Teerenstra, S., & Roes, K. C. B. (2016) · BMC Medical Research Methodology · doi:10.1186/s12874-016-0122-6 · Cited by 90
Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting
Klaveren, D. V., Balan, T. A., Steyerberg, E. W., & Kent, D. M. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.029 · Cited by 88
Self-citation
Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials
Burke, J. F., Hayward, R. A., Nelson, J., & Kent, D. M. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000497 · Cited by 85
Self-citation
A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement
Shah, F. A., Meyer, N. J., Angus, D. C., Awdish, R., Azoulay, É., Calfee, C. S., Clermont, G., Gordon, A. C., Kwizera, A., Leligdowicz, A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1908st · Cited by 86
A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint
Hoogland, J., IntHout, J., Belias, M., Rovers, M. M., Riley, R. D., Harrell, F. E., Moons, K. G. M., Debray, T. P. A., & Reitsma, J. B. (2021) · Statistics in Medicine · doi:10.1002/sim.9154 · Cited by 79
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77
Self-citation
Effects of a population-based, person-centred and integrated care service on health, wellbeing and self-management of community-living older adults: A randomised controlled trial on Embrace
Spoorenberg, S. L. W., Wynia, K., Uittenbroek, R. J., Kremer, H. P. H., & Reijneveld, S. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190751 · Cited by 77
Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death
Fustolo‐Gunnink, S. F., Fijnvandraat, K., Klaveren, D. V., Stanworth, S. J., Curley, A., Onland, W., Steyerberg, E. W., de Kort, E. H. M., d’Haens, E. J., Hulzebos, C. V., et al. (2019) · Blood · doi:10.1182/blood.2019000899 · Cited by 77
Predictive approaches to heterogeneous treatment effects: a scoping review
Rekkas, A., Paulus, J. K., Raman, G., Wong, J. B., Steyerberg, E. W., Rijnbeek, P. R., Kent, D. M., & Klaveren, D. V. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01145-1 · Cited by 80
Self-citation
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
Basu, S., Raghavan, S., Wexler, D. J., & Berkowitz, S. A. (2017) · Diabetes Care · doi:10.2337/dc17-2252 · Cited by 74
Multimorbidity and Evidence Generation
Weiss, C. O., Varadhan, R., Puhan, M. A., Vickers, A. J., Bandeen‐Roche, K., Boyd, C. M., & Kent, D. M. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2660-5 · Cited by 73
Self-citation
Genetic heterogeneity: Challenges, impacts, and methods through an associative lens
Woodward, A., Urbanowicz, R. J., Naj, A. C., & Moore, J. H. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22497 · Cited by 71
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer
Willke, R. J., Zheng, Z., Subedi, P., Althin, R., & Mullins, C. D. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-185 · Cited by 72
Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine
Ryder, J. R., Kaizer, A. M., Jenkins, T. M., Kelly, A. S., Inge, T. H., & Shaibi, G. Q. (2019) · Obesity · doi:10.1002/oby.22369 · Cited by 71
Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects
van der Leeuw, J., Ridker, P. M., van der Graaf, Y., & Visseren, F. L. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu004 · Cited by 68
Cardiovascular Risk and Statin Use in the United States
Johansen, M. E., Green, L. A., Sen, A., Kircher, S. M., & Richardson, C. R. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1641 · Cited by 67
Experimental Designs to Optimize Treatments for Individuals
Davidson, K. W., Silverstein, M., Cheung, K., Paluch, R. A., & Epstein, L. H. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.5801 · Cited by 65
Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index
Deckers, K., Köhler, S., Ngandu, T., Antikaínen, R., Laatikainen, T. K., Soininen, H. S., Strandberg, T. E., Verhey, F. R. J., Kivipelto, M., & Solomon, A. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12281 · Cited by 67
Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination in Community-Dwelling Veterans
Richardson, D. M., Medvedeva, E. L., Roberts, C. B., & Linkin, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ261 · Cited by 65
Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention
Yeh, R. W., Normand, S.-L. T., Wolf, R. E., Jones, P. G., Ho, K. K. L., Cohen, D. J., Cutlip, D. E., Mauri, L., Kugelmass, A. D., Amin, A. P., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.045229 · Cited by 63
Propensity score weighting for causal subgroup analysis
Yang, S., Lorenzi, E., Papadogeorgou, G., WOJDYLA, D. M., Li, F., & Thomas, L. E. (2021) · Statistics in Medicine · doi:10.1002/sim.9029 · Cited by 66
Transesophageal Echocardiography in Cryptogenic Stroke and Patent Foramen Ovale
Wessler, B. S., Thaler, D. E., Ruthazer, R., Weimar, C., Tullio, M. R. D., Elkind, M. S. V., Homma, S., Lutz, J. S., Mas, J., Mattle, H. P., et al. (2013) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.113.000807 · Cited by 62
Self-citation
Pragmatic trials and implementation science: grounds for divorce?
Pawson, R. (2019) · BMC Medical Research Methodology · doi:10.1186/s12874-019-0814-9 · Cited by 60
Effect of inborn vs. outborn delivery on neurodevelopmental outcomes in infants with hypoxic–ischemic encephalopathy: secondary analyses of the NICHD whole-body cooling trial
Natarajan, G., Pappas, A., Shankaran, S., Laptook, A. R., Walsh, M. C., McDonald, S. A., Ehrenkranz, R. A., Tyson, J. E., Goldberg, R. N., Bara, R., et al. (2012) · Pediatric Research · doi:10.1038/pr.2012.103 · Cited by 60
A randomized trial of antibiotic prophylaxis for the prevention of surgical site infection after open mesh-plug hernia repair
Mazaki, T., Mado, K., Masuda, H., Shiono, M., Tochikura, N., & Kaburagi, M. (2014) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2013.01.047 · Cited by 57
Why try to predict ICU outcomes?
Power, G. S., & Harrison, D. A. (2014) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000136 · Cited by 57
Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018
Loder, E., & Rizzoli, P. B. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13375 · Cited by 58
On the Undiffusion of Established Practices
Davidoff, F. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0167 · Cited by 56
Prediction of responders for outcome measures of Locomotor Experience Applied Post Stroke trial
Dobkin, B. H., Nadeau, S. E., Behrman, A. L., Wu, S. S., Rose, D. K., PhD, Bowden, M. G., Studenski, S. A., Lu, X., & Duncan, P. W. (2014) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2013.04.0080 · Cited by 56
Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data
Stuart, E. A., & Rhodes, A. (2016) · Evaluation Review · doi:10.1177/0193841x16660663 · Cited by 59
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
Hutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 57
Effect of Blood Pressure Control on Long‐Term Risk of End‐Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease
Ku, E., Sarnak, M. J., Toto, R. D., McCulloch, C. E., Lin, F., Smogorzewski, M. J., & Hsu, C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012749 · Cited by 53
Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment
Basu, S., Sussman, J. B., & Hayward, R. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1756 · Cited by 51
Self-citation
Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions
Sutherland, J. J., Daly, T. M., Liu, X., Goldstein, K., Johnston, J. A., & Ryan, T. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118991 · Cited by 51
Individualized Cost-Effectiveness Analysis
Ioannidis, J. P. A., & Garber, A. M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001058 · Cited by 50
Self-citation
The “average” treatment effect: A construct ripe for retirement. A commentary on Deaton and Cartwright
Subramanian, S. V., Kim, R., & Christakis, N. A. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2018.04.027 · Cited by 50
Subgroup balancing propensity score
Jing, D., Zhang, J. L., Zeng, S., & Li, F. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280219870836 · Cited by 50
Novel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 51

Authors: Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A.
Affiliations: Tufts Medical Center (US)
John Radcliffe Hospital (GB)
University of Oxford (GB)
University of Michigan (US)
Corresponding author: Kent, David M
ORCID: Kent, David M
Rothwell, Peter M
Ioannidis, John PA
Hayward, Rodney A
Venue: Trials
Publisher: Springer Science and Business Media LLC
Published: 2010-08-12
Volume: 11
Issue: 1
Pages: 85-85
ISSN: 1745-6215 (ISSN-L)
DOI: 10.1186/1745-6215-11-85
PMC: PMC2928211
OpenAlex: W2128780239
Cited by: 504
References: 72
Citations by year: 2026: 32 · 2025: 20 · 2024: 33 · 2023: 26 · 2022: 25 · 2021: 43 · 2020: 32 · 2019: 42 · 2018: 36 · 2017: 37 · 2016: 41 · 2015: 31 · 2014: 39 · 2013: 15 · 2012: 28
FWCI: 17.70
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/2.0 (tdm)
Locations: Trials (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Pfizer
National Institutes of Health (P60DK20572)
Quality Enhancement Research Initiative
National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020572, P60 DK 20572)
National Institute of Neurological Disorders and Stroke (R01NS062153)
National Center for Research Resources (U54 RR023562)
Topics: Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
Keywords: treatment effect heterogeneity, subgroup analysis, clinical trial reporting, treatment risks and benefits, risk stratification
MeSH terms: Clinical Trials as Topic, Humans, Risk Factors, Therapeutics, Reproducibility of Results, Multivariate Analysis, Risk Assessment, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks